In Canada, invasive meningococcal disease (IMD) has been characteristics of 9 cases of invasive serogroup B, serotype 2a, ET15 N. meningitidis found in Canada since 1993. This genoa major public-health issue during the last decade. From 1985 to 1993, there was an annual increase in the national incidence type may be especially interesting to public-health officials, because of its emergence following mass immunization to conof IMD that was associated with the emergence of a new serogroup C clone. Multilocus enzyme electrophoresis placed trol serogroup C:ET15 disease, its potential for epidemic disease (given the behavior of its serogroup C counterpart), and this clone in the electrophoretic type (ET) 37 complex [1] but distinguished it by identification of a unique allelic variant the lack of an effective vaccine for serogroup B N. meningitidis. for the enzyme fumarase [2] . Isolates belonging to this clone, designated ET15, were predominantly serotype 2a, subtypes Methods P1. 2, 5 . From 1988 to 1993, the percentage of all laboratoryconfirmed invasive meningococcal disease in Canada attributIn Canada, IMD is nationally notifiable according to standardized case definitions [9] . The Laboratory Centre for Disease Conable to serogroup C:ET15 increased from 2.0% to 51.8%. Epitrol (LCDC) maintains a national database that correlates case-bydemiologically, ET15 was associated with a significant increase case epidemiologic reports with results from laboratory evaluation.
in IMD incidence among persons 5 -19 years old and a signifiThe epidemiologic reports include the date of disease onset and cant increase in the case fatality rate for all ages [3] . In response the patient's age, sex, residence (health unit), clinical syndrome, to this increase in serogroup C disease, there were 9 mass and outcome.
immunization campaigns (defined as ú20,000 people immuAll sterile-site meningococcal isolates are forwarded to the nized in a campaign) against meningococcal disease in Canada LCDC for serogrouping, serotyping, and serosubtyping at the Nabetween 1992 and 1994. Serogroup C:ET15 has also been intional Laboratory for Bacterial Diseases [10] . Multilocus enzyme creasingly responsible for epidemic and endemic disease in the electrophoresis and pulsed-field gel electrophoresis, as described United States [4] , England and Wales [5] , and the Czech Repreviously [2, 7] , are used routinely to characterize all serogroup public [6] .
C meningococcal isolates as well as serogroup B isolates that are suspected of belonging to the ET37 complex.
In contrast to serogroup C:ET15, which has caused several community and institutional outbreaks [7] 
patients was unknown, although 2 would not have been eligible different capsular polysaccharides co-colonize the human nasopharynx. The rate at which this occurs has yet to be estimated. to receive publicly funded meningococcal vaccine as part of any immunization campaign because of age (case 3, 48 years,
In the US Pacific Northwest, capsular switching from serogroup B to C was described among a group of ET5-complex isolates exceeding maximum age of 20 years) or location (case 4, from a population in a nonimmunized area of New Brunswick). The during a 1994 -1995 outbreak. Molecular genetic analysis of these isolates suggested that the capsule-switching phenomeremaining 3 patients with unknown vaccine status would have been eligible for publicly funded vaccine because of their ages non resulted from genetic transformation and recombination at a locus within the capsule-biosynthetic (syn) operon [12] . The and locations of residence.
All of the B:ET15 isolates were serotype 2a. Seven were C-to-B capsular switch reported here is the reverse of this Bto-C switch, but analogous genetic events may have preceded subtype P1.2,5 and 2 were nonsubtypeable (P1. -).
In 1993, 1994, and 1995 there were, respectively, 393, 361, the appearance of B:ET15 isolates in Canada. Two general types of explanation could be advanced for the and 305 cases of invasive meningococcal disease in Canada, corresponding to yearly incidences of 1.4, 1.3, and 1.0/100,000, recent appearance of these B:ET15 strains. The first invokes a fitness advantage for B-encapsulated variants of a prevalent Crespectively. Of all laboratory-confirmed cases during this period, 39% were caused by group B strains, of which 36.4% encapsulated genotype. This could occur if the B-encapsulated variants were subject to less intense selection pressure from were nonserotypeable, 28.7% serotype 4, 16.8% serotype 15, 8.3% serotype 14, 3.4% serotype 2a, and 2.1% serotype 2b.
the immune systems of the population of human hosts, because they carry a polysaccharide antigen that is both different from Serogroup C strains accounted for 48.6% of all laboratoryconfirmed cases during the same time period. Among these, that of the more prevalent group C strains (to which many potential hosts would already possess antibodies) and less im-87.9% were serotype 2a, 8.9% were nonserotypeable, and 3.2% were other serotypes, including 14, 15, 4, and 2b. Between munogenic [13] . The resulting fitness advantage of the B variants may be modest. However, because the background chro-1993 and 1995, ET15 accounted for 93% of all serogroup C isolates in Canada.
mosomal genotypes (here represented by the 2a:P1.2,5:ET15 array of markers) of the two capsular variants would be extremely similar, one might expect the B and C forms to occupy Discussion very similar ecologic niches. Thus, one might reasonably expect that whatever factors have led to the recent rapid increase This report describes the appearance, in Canada, of a variant form of a prevalent invasive serogroup C meningococcal genoin prevalence of C:ET15 in Canada [3] might also apply to B:ET15, and perhaps that intergenotypic competition between type (C:2a:P1.2,5:ET15), that instead expresses serogroup B capsular polysaccharide.
B:ET15 and its C:ET15 counterpart contributed to the appearance of the former. Meningococcal strains that are genetically similar to each other but express serogroup B or C capsular polysaccharide
We also raise the question of whether the recent appearance of invasive disease due to serogroup B:ET15 strains in Canada antigens have also been described in countries other than Canada [1, 11, 12] . The repeated observation of such variants may be related partly to the widespread use of meningococcal vaccine in response to epidemics of C:ET15 (figure 1). Elemenat different times and places and in different chromosomal backgrounds suggests that they arise frequently in the bacterial tary population genetics theory indicates that the probability of escape from random loss of a new, selectively advantageous population, as meningococcal strains carrying genes specifying / 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect immunity to serogroup C invasive disease. It is important to point out, first, that at least 2 and likely 4 of the 9 patients in reported cases of B:ET15 disease did not receive vaccine (see Results). This would mean that vaccine-induced immunity of these individuals per se cannot be a direct contributing factor in their having contracted IMD due to B:ET15 meningococci. Second, although such protective immunity may indeed have contributed to the recent decline in the overall incidence of group C disease in Canada (figure 1), it is not clear how this factor alone could explain the recent appearance of the B:ET15 variants. If the latter had been present at significant frequencies in the meningococcal population before vaccination, one would expect them to have been observed at that time. However, it should also be clear that it is not possible at present to distinguish conclusively between explanations based on selection B:ET15 in Canada, alternative scenarios should also be considered. Foremost among these is the possibility that insufficient selective advantage of any kind accrues to B:ET15 variants to genetic variant in a population, as well as its rate of frequency increase if it does escape such random loss, is directly proporhave caused their recent rise in frequency among cases of IMD, and that the latter effect is simply what one would expect, given tional to the magnitude of its selective advantage [14] . Thus, one effect of mass vaccination might have been to intensify a moderately high rate of transformation and recombination at the capsular-polysaccharide locus and high prevalence of a selection pressure past a critical threshold, such that the frequency of B:ET15 variants in the nasopharyngeal meningococwell-studied and closely observed genotype (C:ET15) on which selectively neutral B variants would be most likely eventually cal population rose to a point where they began to appear in cases of IMD.
to occur and to be noticed. We plan to test this alternative explanation against the above-mentioned selection-based hyIt is suggestive that 7 of 9 invasive B:ET15 isolates were identified after mass immunization in Québec and Saskatchepothesis, using a molecular population-genetic approach [12] . A switch from serogroup C:ET15 to serogroup B:ET15 may wan, provinces that had carried out the largest campaigns. Québec immunized all persons 6 months to 19 years old be especially significant from a public-health perspective, given the epidemic behavior of C:ET15 and because no vaccine exists (Ç1,613,000 people) between December 1991 and May 1993, and Saskatchewan immunized all persons 2 -19 years old against the B capsular polysaccharide. None of the B:ET15 isolates have occurred as part of an epidemic or cluster, and (Ç258,000 people) in November and December 1993. By providing a large segment of the population with antibody against there have been no new cases of invasive B:ET15 infection since September 1995. This suggests that B:ET15 does not serogroup C capsular polysaccharide, such immunization could have been another factor influencing the relative fitnesses of have the epidemic potential of C:ET15, at least in Canadian host populations at this time. However, comparisons of the closely related strains of N. meningitidis carrying different capsular antigens. It is also noteworthy in this context that invasive epidemiologic behavior of serogroup B:ET15 and serogroup C:ET15 are limited by the small number of isolates, and contin-B:ET15 strains have not yet been identified in the populous provinces of British Columbia or Ontario, which used smallerued surveillance will be necessary to document further this behavior in Canada and elsewhere, as well as to study the scale mass immunization campaigns to control epidemic C:ET15. Though circumstances differed in each province prior possible relationship with mass immunization. The potential for capsular switching may be one of the many factors publicto immunization, the latter two provinces targeted specific health units and communities, while Québec and Saskatchewan health officials should consider when planning targeted or mass immunization for epidemic or endemic meningococcal disease. provided vaccine to large segments of entire provincial populations.
Another form of selection-based explanation is that vaccina-
